REQUEST A DEMO
Total
USD $0.00
Search more companies

Innovapharm Polska Sp. z o.o. (Poland)

Main Activities: Chemical and Allied Products Merchant Wholesalers
Secondary Activities: Construction of Buildings | Other Miscellaneous Nondurable Goods Merchant Wholesalers | Wholesale Trade Agents and Brokers | Other Depository Credit Intermediation
Full name: Innovapharm Polska Sp. z o.o. Profile Updated: May 22, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Polish Download a sample report

Innovapharm Polska Sp. z o.o is a pharmaceutical company that offers pharmaceutical products and services, focusing on products in various segments. They operate as an Exclusive Distributor of Cross Linked and Non Cross Linked Hyaluronic Acid Hyamira Made in Italy, with a line of products certified by internationally and domestically authorized organizations.

Headquarters
Ul. Annopol 3
Warsaw; Mazowieckie; Postal Code: 03-236

Contact Details: Purchase the Innovapharm Polska Sp. z o.o. report to view the information.

Website: http://www.innovapharm.pl

Basic Information
Total Employees:
Purchase the Innovapharm Polska Sp. z o.o. report to view the information.
Outstanding Shares:
Purchase the Innovapharm Polska Sp. z o.o. report to view the information.
Registered Capital:
Purchase the Innovapharm Polska Sp. z o.o. report to view the information.
Incorporation Date:
June 21, 2018
Key Executives
Purchase this report to view the information.
President
Ownership Details
Purchase this report to view the information.
50%
Purchase this report to view the information.
50%
Subsidiaries
Regal Development Sp. z o.o.
100%
Company Performance
Financial values in the chart are available after Innovapharm Polska Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
22.34%
Total operating revenue
22.33%
Operating profit (EBIT)
59.53%
EBITDA
59.31%
Net Profit (Loss) for the Period
79.79%
Total assets
10.67%
Total equity
40.5%
Operating Profit Margin (ROS)
6.57%
Net Profit Margin
8.02%
Return on Equity (ROE)
6.3%
Debt to Equity Ratio
-3.11%
Quick Ratio
-0.01%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?